New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
09:18 EDTMM, RUBI, TTWO, SODA, P, BMY, GSK, CSIQ, PLUG, SNE, ENZY, ISIS, PTX, FOSL, CLDXOn The Fly: Pre-market Movers
HIGHER: Pernix Therapeutics (PTX), up 42% after acquiring TREXIMET tablets for migraine from GlaxoSmithKline (GSK)... Isis Pharmaceuticals (ISIS), up 9.6% after Phase 2 results for ISIS-GCGR for diabetes reported... Canadian Solar (CSIQ), up 1.7% after partnering with Ikea to build 3.6MW solar systems... Pandora (P), up 1.4% following upgrade at Raymond James... Rubicon Project (RUBI), up 22% after upgraded at Oppenheimer and RBC Capital following its Q1 earnings report... Celldex (CLDX), up 10.5% after announcing collaboration agreement with Bristol-Myers (BMY)... Millennial Media (MM), up 3.4% after CEO Barrett purchases 291K shares. LOWER: Sony (SNE), down 5.6% after reporting FY13 results, guiding to losses in FY14... DOWN AFTER EARNINGS: Fossil (FOSL), down 6.5%... Enzymotec (ENZY), down 8.6%... Plug Power (PLUG), down 6.6%... SodaStream (SODA), down 3.2%... Take-Two (TTWO), down 3.5%.
News For SNE;P;CLDX;PLUG;SODA;FOSL;CSIQ;TTWO;PTX;GSK;RUBI;ISIS;BMY;MM;ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
10:36 EDTSNE, TTWOElectronic Arts advances after analysts positive on E3 showing
Subscribe for More Information
10:00 EDTTTWOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:30 EDTPGoogle competing with itself after unveiling free music service, Bloomberg says
Subscribe for More Information
07:29 EDTBMYFDAnews to hold a summit
Subscribe for More Information
07:10 EDTTTWOTake-Two upgraded to Buy with $35 target at Jefferies
Subscribe for More Information
06:44 EDTTTWOTake-Two upgraded to Buy from Hold at Jefferies
Price target $35.
June 23, 2015
18:04 EDTISISIsis Pharma granted FDA orphan status for treatment of familial chylomicronemia
Subscribe for More Information
12:08 EDTPPandora down 1% after Google launches free music service
Subscribe for More Information
12:05 EDTPGoogle launches free, ad-supported music service in U.S.
Google (GOOG) announced via a blob post that Google Play Music now has a "free, ad-supported version" in the U.S. It stated, "Our team of music experts, including the folks who created Songza, crafts each station song by song so you donít have to. If youíre looking for something specific, you can browse our curated stations by genre, mood, decade or activity, or you can search for your favorite artist, album or song to instantly create a station of similar music." Shares of Pandora (P) ticked lower following Google's announcement.
08:58 EDTISISIsis Pharmaceuticals shares not reflecting SMA data, says Needham
Subscribe for More Information
07:25 EDTGSKPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
07:07 EDTCSIQCanadian Solar subsidiary completes sale of LunarLight to Blue Earth
Subscribe for More Information
06:05 EDTSNENo clear prospects for PC component suppliers until July, DigiTimes reports
There are no clear business prospects for PC component suppliers until July, reports DigiTimes. According to sources in the supply chain, Intel's decision to delay the launch of its Skylake platform has weakened market demand for notebooks and other PC systems. The planned release of Microsoft (MSFT) Windows 10 may also affect the production of PC makers. Reference Link
June 22, 2015
09:51 EDTSNESony to launch 1-terabyte PlayStation 4 in July
Subscribe for More Information
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:01 EDTGSKPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizerís portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizerís legal advisors for the transaction were Ropes & Gray and Clifford Chance.
07:01 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx in Phase 2 study
Subscribe for More Information
06:46 EDTRUBIRubicon Project weakness a buying opportunity, says B. Riley
B. Riley recommends buying Rubicon Project on recent weakness created by insider/VC selling and distribution and reports about the Safari ad blocker. The firm said Rubicon continues to add premium publishers to its platform and improve buyer tools and could be free-cash-flow breakeven by 2015. B. Riley rates shares a Buy with a $26 price target.
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitmanís lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Childrenís Hospital, Professor Whitmanís lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvardís Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitmanís lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use